Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation

• Published in: Cell death & disease Vol. 12; no. 1; p. 78
• Main Authors: Chen, Ao, Chen, Zhangwei, Zhou, You, Wu, Yuan, Xia, Yan, Lu, Danbo, Fan, Mengkang, Li, Su, Chen, Jinxiang, Sun, Aijun, Zou, Yunzeng, Qian, Juying, Ge, Junbo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.01.2021; Springer Nature B.V; Nature Publishing Group
• Subjects: 13/1; 13/31; 14/34; 631/80/82; 692/699/75; 82/58; 82/80; Animals; Antibodies; Anticholesteremic Agents - pharmacology; Anticholesteremic Agents - therapeutic use; Apoptosis; Biochemistry; Biomedical and Life Sciences; Caspase-1; Cell Biology; Cell Culture; Cell viability; Dehydrogenases; Disease; Energy metabolism; Fibrosis; Heart; Hospitals; Humans; Hypoxia; IL-1β; Immunology; Inflammasomes; Inflammasomes - metabolism; L-Lactate dehydrogenase; Lactic acid; Life Sciences; Male; Mice; Mitochondria; Molecular modelling; Muscle contraction; Myocardial infarction; Myocardial Reperfusion Injury - drug therapy; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Oxidative metabolism; Oxidative phosphorylation; Pathogenesis; Phosphorylation; Propidium iodide; Proteins; Proteomics; Pyroptosis; Reactive oxygen species; Rosuvastatin Calcium - pharmacology; Rosuvastatin Calcium - therapeutic use; Statins; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-021-03389-1

Coronary microembolization (CME), a common reason for periprocedural myocardial infarction (PMI), bears very important prognostic implications. However, the molecular mechanisms related to CME remain largely elusive. Statins have been shown to prevent PMI, but the underlying mechanism has not been identified. Here, we examine whether the NLRP3 inflammasome contributes to CME-induced cardiac injury and investigate the effects of statin therapy on CME. In vivo study, mice with CME were treated with 40 mg/kg/d rosuvastatin (RVS) orally or a selective NLRP3 inflammasome inhibitor MCC950 intraperitoneally (20 mg/kg/d). Mice treated with MCC950 and RVS showed improved cardiac contractile function and morphological changes, diminished fibrosis and microinfarct size, and reduced serum lactate dehydrogenase (LDH) level. Mechanistically, RVS decreased the expression of NLRP3, caspase-1, interleukin-1β, and Gasdermin D N-terminal domains. Proteomics analysis revealed that RVS restored the energy metabolism and oxidative phosphorylation in CME. Furthermore, reduced reactive oxygen species (ROS) level and alleviated mitochondrial damage were observed in RVS-treated mice. In vitro study, RVS inhibited the activation of NLRP3 inflammasome induced by tumor necrosis factor α plus hypoxia in H9c2 cells. Meanwhile, the pyroptosis was also suppressed by RVS, indicated by the increased cell viability, decreased LDH and propidium iodide uptake in H9c2 cells. RVS also reduced the level of mitochondrial ROS generation in vitro. Our results indicate the NLRP3 inflammasome-dependent cardiac pyroptosis plays an important role in CME-induced cardiac injury and its inhibitor exerts cardioprotective effect following CME. We also uncover the anti-pyroptosis role of RVS in CME, which is associated with regulating mitochondrial ROS.